Green Thumb Industries Inc.

# Business Overview: Green Thumb Industries Inc. (OTCQX: GTBIF)

---

Executive Summary

Green Thumb Industries Inc. is a U.S. cannabis consumer packaged goods (CPG) company and retailer, founded in 2014 and headquartered in Chicago. The company began operating in Illinois in 2015 and has grown into one of the larger multistate cannabis operators, cultivating and manufacturing its own cannabis products while also operating a national retail footprint of licensed dispensaries, including its RISE Dispensaries chain.

Unlike many Canadian-incorporated multistate operators that file as foreign private issuers, Green Thumb reports as a U.S. domestic filer on Form 10-K. The company operates in 14 U.S. states with 113 open retail locations and 20 owned manufacturing facilities, generating $1.2 billion in 2025 revenue despite operating in an industry still illegal under federal law.

---

1. Core Business Model & How They Work

Green Thumb grows and processes its own cannabis, manufactures branded CPG products, and sells them both wholesale to third-party licensed retailers and directly through its own retail stores.

[ Cultivation & Processing (owned facilities) ] ➡️ [ Cannabis CPG Manufacturing (20 facilities) ] ➡️ [ Wholesale to Third-Party Retailers (CPG: 29% of revenue) | Direct Retail via RISE Dispensaries (Retail: 71% of revenue) ] ➡️ [ Revenue, net of heavy 280E-driven tax burden ]

Key Operational Drivers

1. Retail-Weighted Revenue Mix: Retail represented 71% of 2025 revenue versus 29% for CPG (wholesale) — Green Thumb captures more margin by selling direct-to-consumer through its own dispensaries rather than relying primarily on wholesale.
2. Selective Vertical Integration: The company describes itself as "vertically integrated" specifically in certain licenses, such as Florida's and New York's, rather than uniformly across all 14 states — reflecting the patchwork of state-by-state cannabis licensing regimes.
3. Brand Monetization via RYTHM, Inc.: In 2025, Green Thumb sold the intellectual property for its brand portfolio (&Shine, Beboe, Dogwalkers, Doctor Solomon's, Good Green, incredibles, RYTHM) to RYTHM, Inc. (RYM) and now licenses the brands back for use in its existing markets, while retaining roughly 33% ownership of RYM's common stock — monetizing brand IP while keeping an equity stake in the upside.
4. Federal Illegality & Section 280E: Cannabis remains a federal Schedule I controlled substance, making Green Thumb's operations illegal under federal law despite full state-law compliance. This triggers Section 280E of the tax code, which disallows normal business expense deductions — reflected in a 2025 effective tax rate of roughly 56% ($147.3 million of tax on $263.4 million of pre-tax income).
5. Potential Rescheduling Catalyst: A December 18, 2025 Executive Order directed cannabis rescheduling to Schedule III, which the company notes would eliminate Section 280E's applicability — a major potential tax-cost reduction, though rescheduling would not immediately change the legal status of state programs or federal illegality generally.

---

2. Business Segments

┌───────────────────────────────────┐
│     Green Thumb Industries Inc.      │
└────────────────┬──────────────────┘
                  │
     ┌────────────┴─────────────┐
     ▼                           ▼
┌───────────────────┐    ┌─────────────────────┐
│  Retail               │    │  CPG / Wholesale        │
│  (RISE Dispensaries     │    │  (branded cannabis       │
│   + other banners;       │    │   products sold to        │
│   113 locations,          │    │   third-party retailers)   │
│   71% of revenue)          │    │  29% of revenue              │
└───────────────────┘    └─────────────────────┘

Retail

113 open dispensary locations across 14 states, operating primarily under the RISE Dispensaries banner. The larger of the two revenue streams, capturing full retail margin on products sold directly to consumers.

CPG / Wholesale

Cannabis consumer packaged goods manufactured at 20 owned facilities and sold to third-party licensed retailers in states where Green Thumb does not operate its own stores or chooses to also sell wholesale.

---

3. Product Portfolio

---

4. Competitive Landscape

      U.S. CANNABIS MULTISTATE OPERATOR POSITIONING
┌──────────────────────────────────────────────────────┐
│ High │                                                   │
│  ▲   │   [Green Thumb]        [Curaleaf] [Trulieve]       │
│  R   │   (14-state footprint,  (larger multistate           │
│  E   │    retail-weighted,      operators)                  │
│  T   │    brand licensing)                                   │
│  A   │                                                      │
│  I   │  [Single-state/regional operators]                     │
│  L   │  (smaller scale, limited diversification)               │
│      │                                                      │
│ Low  │  [Illicit market] [Hemp-derived THC products]            │
│      │  (untaxed, 280E-exempt, illegal or regulatory gray area)  │
│      └───────────────────────────────────────────────────► │
│       Low            MULTI-STATE SCALE                High  │
└──────────────────────────────────────────────────────┘

Green Thumb competes against other multistate cannabis operators (e.g., Curaleaf, Trulieve), single-state and regional cannabis companies, and — critically — the illicit market and hemp-derived THC products, which the company explicitly notes have a structural pricing advantage because they escape both Section 280E and state cannabis excise taxes. The filing also flags that federal rescheduling could eventually attract new, non-cannabis-specialist competitors (e.g., larger consumer products or pharmaceutical companies) into the space.

---

5. Strategic Strengths & Risks

Strengths (The Moat)

• Multistate licensing portfolio: Operating licenses across 14 states, several with vertically integrated status (e.g., Florida, New York), represent a scarce, difficult-to-replicate regulatory asset — state cannabis licenses are capped in number and hard to obtain.
• Retail-weighted revenue mix with brand monetization: Capturing 71% of revenue through owned retail, while also monetizing brand IP via the RYM licensing arrangement, gives Green Thumb more margin capture and optionality than wholesale-only competitors.
• Scale manufacturing footprint: 20 owned manufacturing facilities support consistent product quality and supply across a broad geographic footprint, a meaningful barrier for smaller single-state competitors.

Risks

• Section 280E tax burden: A ~56% effective tax rate in 2025 (reflecting disallowed business expense deductions under federal tax law) is a direct, structural cost disadvantage that would not exist in almost any other legal U.S. industry.
• Price compression: Gross margin fell to 48.9% from 52.9% in 2024, which the company attributes to price compression — a sign of intensifying competitive and/or oversupply pressure in mature cannabis markets.
• Federal illegality overhang: Despite the December 2025 rescheduling Executive Order, cannabis operations remain federally illegal, exposing the company to banking access limitations, interstate commerce restrictions, and ongoing legal/regulatory uncertainty.
• Hemp-derived THC competition: Products that fall outside cannabis regulation (and thus avoid 280E and state excise taxes) represent a growing, lower-cost competitive threat that operates largely outside the same tax and licensing framework Green Thumb must bear.

---

6. Financial Overview

---

7. Summary Conclusion

Green Thumb Industries has built one of the larger U.S. multistate cannabis footprints by combining scarce state licenses, a retail-weighted revenue model, and a capital-efficient brand-licensing arrangement with RYTHM, Inc. The business generates genuinely healthy core profitability (Normalized EBITDA margin near 30%), but that profitability is earned despite — not because of — the federal legal environment, which imposes a roughly 56% effective tax rate through Section 280E. The single biggest catalyst on the horizon is the December 2025 Executive Order directing cannabis rescheduling to Schedule III, which, if it ultimately eliminates 280E's applicability, could meaningfully re-rate the company's after-tax economics; until then, price compression in mature markets and hemp-derived THC competition remain the more immediate operating risks.